chroman-2-yl-acetic acid ethyl ester | 33950-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: chroman-2-yl-acetic acid ethyl ester
• 英文别名: ethyl 3,4-dihydro-2H-1-benzopyran-2-acetate；ethyl 2-(3,4-dihydro-2H-chromen-2-yl)acetate
• CAS: 33950-77-5
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: PYHRGVPRATVSFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Synthesis of 2-Acyl substituted chromanes and intermediates thereof
  申请人：——

  公开号：US20030233002A1

  公开（公告）日：2003-12-18

  Novel processes for producing enantiomerically enriched and enantiomerically pure compositions of 2-acyl substituted chromane compounds, and 2-acylchromane compounds that are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors are disclosed. Further disclosed are processes for producing salts such as acid addition salts for such enantiomerically enriched compositions.

  本发明揭示了用于生产富含对映体和对映纯2-酰基取代基色酮化合物的新工艺，以及用于生产血小板聚集抑制剂的中间体2-酰基色酮化合物和/或它们本身是有效的血小板聚集抑制剂的工艺。还揭示了用于生产酸盐等对这些富含对映体的成分的工艺。
• US5925662A
  申请人：——

  公开号：US5925662A

  公开（公告）日：1999-07-20
• US6903227B2
  申请人：——

  公开号：US6903227B2

  公开（公告）日：2005-06-07
• [EN] METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR<br/>[FR] PROCEDES DE PRODUCTION DE CHROMANES AMINO SUBSTITUES ET INTERMEDIAIRES CORRESPONDANTS
  申请人：COR THERAPEUTICS INC

  公开号：WO2001087871A2

  公开（公告）日：2001-11-22

  Disclosed are processes for producing chromane compounds, preferably 2-(6-aminochroman-2-yl) acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.
• [EN] SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF<br/>[FR] SYNTHESE DE CHROMANES A SUBSTITUTION 2-ACYLE ET DES INTERMEDIAIRES DE CEUX-CI
  申请人：COR THERAPEUTICS INC

  公开号：WO2001092250A2

  公开（公告）日：2001-12-06

  Novel processes for producing enantiomerically enriched and enantiomerically pure compositions of 2-acyl substituted chromane compounds, and 2-acylchromane compounds that are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors are disclosed. Further disclosed are processes for producing salts such as acid addition salts for such enantiomerically enriched compositions.